ARDEPARIN SODIUM - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ardeparin sodium and what is the scope of freedom to operate?

Ardeparin sodium is the generic ingredient in one branded drug marketed by Pharmacia And Upjohn and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for ARDEPARIN SODIUM

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	57
DailyMed Link:	ARDEPARIN SODIUM at DailyMed

US Patents and Regulatory Information for ARDEPARIN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	NORMIFLO	ardeparin sodium	INJECTABLE;INJECTION	020227-001	May 23, 1997		DISCN	Yes	No
Pharmacia And Upjohn	NORMIFLO	ardeparin sodium	INJECTABLE;INJECTION	020227-002	May 23, 1997		DISCN	Yes	No

Ardeparin Sodium Market Dynamics, Financial Trajectory, and Patent Position

Last updated: September 4, 2026

Ardeparin sodium is a discontinued low-molecular-weight heparin anticoagulant formerly developed as Normiflo by Wyeth-Ayerst Laboratories. The FDA approved the product in the 1990s for prevention of deep-vein thrombosis after orthopedic surgery, but the product did not establish a durable commercial market in the United States. Its financial trajectory therefore consists primarily of development and regulatory investment, followed by commercial withdrawal, rather than a conventional launch-to-growth lifecycle.

No current U.S. revenue base, active commercial franchise, or meaningful exclusivity position is associated with ardeparin sodium. The drug has no current role in the U.S. anticoagulant market, where enoxaparin, unfractionated heparin, fondaparinux, direct oral anticoagulants, and other low-molecular-weight heparins are the principal alternatives.

What is ardeparin sodium and how was it used?

Ardeparin sodium is a low-molecular-weight heparin derived from unfractionated heparin. Like other low-molecular-weight heparins, it produces anticoagulant activity primarily through potentiation of antithrombin and inhibition of factor Xa, with lesser activity against thrombin compared with unfractionated heparin.

The product was developed for subcutaneous administration and was evaluated principally for prevention of postoperative venous thromboembolism. Its intended commercial setting was orthopedic surgery, particularly total knee replacement and related procedures.

Attribute	Ardeparin sodium
Drug class	Low-molecular-weight heparin
Former U.S. brand	Normiflo
Developer	Wyeth-Ayerst Laboratories
Administration	Subcutaneous injection
Primary target market	Postoperative thromboprophylaxis
FDA status	Approved, subsequently withdrawn from U.S. commercial use
Current U.S. commercial status	No marketed product
Biosimilar pathway	Not applicable
Generic pathway	Theoretical 505(j) pathway, subject to FDA requirements

FDA approval did not translate into a sustained commercial franchise. The product’s market position was weakened by competition from established low-molecular-weight heparins, particularly enoxaparin, and by the operational burden of injectable anticoagulant manufacturing and distribution.

When did ardeparin sodium lose market exclusivity?

Ardeparin sodium no longer has a meaningful U.S. market-exclusivity position. The relevant commercial issue is product withdrawal, not the expiration of a current patent or regulatory exclusivity period.

FDA records identify Normiflo under NDA 20-946. The product received FDA approval in the 1990s and was later withdrawn from the U.S. market. FDA’s withdrawal records distinguish the product’s regulatory history from an active marketed product with continuing exclusivity. [1][2]

Ardeparin sodium exclusivity timeline

Period	Event	Commercial consequence
1990s	FDA approval of Normiflo under NDA 20-946	Regulatory entry obtained
Late 1990s to early 2000s	Product commercialization did not develop into a durable franchise	Limited or absent commercial scale
Around 2000	U.S. withdrawal from commercial use is reported in FDA and drug-reference records	U.S. revenue opportunity ended
Current period	No active U.S. commercial product or meaningful listed-exclusivity position	No practical branded exclusivity

The approval history should not be interpreted as evidence of sustained U.S. sales. In pharmaceutical development, an approved NDA can remain commercially insignificant if the sponsor does not achieve manufacturing readiness, distribution scale, reimbursement access, or physician adoption.

What patents protect ardeparin sodium?

No active U.S. patent estate with material commercial significance is associated with ardeparin sodium today. The drug is an older heparin-derived molecule, and any historical composition, process, formulation, or use patents would generally be expected to have expired or become commercially irrelevant.

The principal potential patent categories were:

1. Composition or molecular-weight distribution claims covering the low-molecular-weight heparin.
2. Manufacturing claims covering depolymerization, purification, and control of anticoagulant activity.
3. Formulation claims covering injectable aqueous solutions.
4. Method-of-use claims covering prevention of postoperative deep-vein thrombosis.

A complete patent-by-patent analysis would require historical patent-family and Orange Book records. The available regulatory record does not support identifying a currently enforceable patent barrier that could block U.S. entry.

Does the Orange Book list ardeparin sodium patents?

Ardeparin sodium does not have a commercially active Orange Book position comparable with marketed branded anticoagulants. The former NDA is not a current platform for an active branded product, and there is no practical basis for treating historical listing activity as a current barrier to competition.

FDA Orange Book protection is tied to listed patents and the status of the reference drug application. Because Normiflo is no longer a marketed U.S. product, its historical NDA status does not create a present-day branded launch defense. [3]

Are there Paragraph IV challenges to ardeparin sodium?

No material current Paragraph IV challenge is associated with ardeparin sodium. Paragraph IV litigation normally arises when a generic applicant files an ANDA referencing an active branded product and certifies that listed patents are invalid, unenforceable, or not infringed.

Ardeparin sodium lacks the commercial conditions that typically generate Paragraph IV activity:

• No active branded U.S. franchise.
• No significant current sales base to target.
• No meaningful listed-patent barrier identified in the current market.
• Limited incentive for a generic applicant to incur development and litigation costs.
• Competition from established anticoagulant products with clearer regulatory and reimbursement pathways.

An applicant could theoretically pursue an abbreviated application if an appropriate reference-product and FDA regulatory pathway were available. That possibility does not create a commercially relevant challenge to Normiflo.

What is the FDA regulatory status of ardeparin sodium?

Ardeparin sodium is not a current U.S. marketed anticoagulant. The FDA approval history is important because it shows that the product achieved regulatory approval but failed to develop into a durable commercial product.

Its regulatory profile differs from a drug that was rejected for lack of efficacy. Available historical records describe the product as approved and later withdrawn from the market. The withdrawal should therefore be analyzed as a commercial and lifecycle event rather than as evidence that ardeparin sodium never obtained FDA approval. [1][2]

No current U.S. labeling, prescribing market, postmarketing sales base, or active promotional infrastructure supports a continuing Normiflo franchise.

How did ardeparin sodium compare with enoxaparin and other anticoagulants?

Ardeparin entered a market in which competitors already had stronger commercial assets. Enoxaparin, dalteparin, and tinzaparin had broader clinical recognition and established hospital procurement channels. Fondaparinux later provided another injectable alternative, while direct oral anticoagulants expanded the market for oral thromboprophylaxis and treatment.

Product	Class	Commercial position relative to ardeparin
Enoxaparin	Low-molecular-weight heparin	Stronger market adoption and broader clinical use
Dalteparin	Low-molecular-weight heparin	Established hospital and oncology-related use
Tinzaparin	Low-molecular-weight heparin	Established non-U.S. and selected specialty markets
Fondaparinux	Synthetic factor Xa inhibitor	Differentiated injectable alternative
Unfractionated heparin	Heparin anticoagulant	Low-cost hospital standard with reversibility and familiarity
Direct oral anticoagulants	Oral factor Xa or thrombin inhibitors	Reduced dependence on injectable prophylaxis in selected indications
Ardeparin	Low-molecular-weight heparin	Failed to sustain a U.S. commercial position

Ardeparin’s clinical similarity to established low-molecular-weight heparins limited differentiation. A new injectable anticoagulant needed to demonstrate a clear advantage in efficacy, bleeding risk, dosing convenience, monitoring, price, or supply reliability. Ardeparin did not create a sufficiently distinct commercial profile.

What financial trajectory did ardeparin sodium have?

Ardeparin sodium followed a failed-commercialization trajectory:

1. Preclinical and clinical development generated research and trial costs.
2. FDA approval created regulatory value but did not establish recurring revenue.
3. Commercial scale was constrained by competition and product lifecycle issues.
4. U.S. withdrawal eliminated future branded sales.
5. The asset transitioned from a potential revenue product to a discontinued development asset.

There is no reliable basis for assigning substantial cumulative U.S. revenue to Normiflo. Public financial reporting from the relevant period did not establish ardeparin sodium as a material revenue contributor for Wyeth. The product should therefore be treated as financially immaterial at the company level, with value concentrated in development optionality rather than realized sales.

Revenue exposure

Financial metric	Assessment
Current U.S. revenue	None identified
Current branded market share	None
Historical peak sales	Not established as material in public company reporting
Revenue concentration risk	None for current sponsors
Remaining royalty stream	No material stream identified
Licensing value	Low without a new formulation, indication, or market-specific opportunity
Generic erosion risk	Theoretical only because there is no active branded market

What manufacturing and intellectual-property barriers affected ardeparin?

Low-molecular-weight heparins are complex biological mixtures rather than single small molecules with a simple chemical synthesis route. Manufacturing requires control of molecular-weight distribution, anticoagulant potency, impurity profile, source material, depolymerization conditions, and batch consistency.

Those characteristics create technical barriers even when conventional patent protection is weak. A potential manufacturer would need to demonstrate comparability and consistent clinical performance, not merely reproduce a nominal active ingredient name.

Key manufacturing issues include:

• Source and quality of unfractionated heparin.
• Control of depolymerization chemistry.
• Molecular-weight distribution.
• Anti-Xa and anti-IIa activity ratios.
• Residual process impurities.
• Sterility and injectable-product controls.
• Batch-to-batch comparability.
• Clinical and regulatory support for substitutability.

These barriers can deter entry without providing the sponsor with durable exclusivity. In ardeparin’s case, technical complexity was not converted into a lasting commercial advantage.

What licensing deals or settlement agreements involve ardeparin sodium?

No material current licensing deal or Paragraph IV settlement involving ardeparin sodium is identified in the public regulatory record. The product’s discontinued status and limited commercial footprint reduce the likelihood of royalty-bearing licensing or antitrust-relevant settlement activity.

There is also no current biosimilar settlement landscape. Biosimilar regulation applies to biologic products under the Public Health Service Act, while ardeparin sodium is treated as a low-molecular-weight heparin drug product rather than a conventional FDA-designated biosimilar reference product. [4]

What generic launch scenarios exist for ardeparin sodium?

A commercial relaunch would be more likely to require a new regulatory and market strategy than a conventional generic launch against Normiflo.

Scenario 1: No re-entry

This is the most probable scenario. The market has established alternatives, and the commercial return would not clearly justify development, manufacturing, clinical comparability, and hospital-contracting costs.

Scenario 2: Generic or abbreviated application

A sponsor could evaluate an ANDA or another FDA pathway, depending on reference-product availability and product-specific requirements. The principal obstacles would be pharmaceutical equivalence, batch consistency, clinical comparability, and market demand.

Scenario 3: Specialty-market relaunch

A relaunch could target a defined surgical, hospital, or international segment. Success would require a differentiated price, supply advantage, dosing profile, or contracting strategy.

Scenario 4: Reformulated product

A reformulated injectable or combination delivery system could create new intellectual-property opportunities. The commercial case would remain weak unless the reformulation solved a significant clinical or operational problem.

How strong is the ardeparin sodium patent estate?

The present patent estate is weak from a commercial-defense perspective. Historical process or formulation patents may have provided protection during development, but there is no indication of a live U.S. patent wall capable of supporting premium pricing or deterring entry.

The asset’s stronger barriers are technical and regulatory rather than patent-based. Those barriers can raise development costs, but they do not create the same market power as enforceable composition or formulation patents attached to a high-revenue product.

Key Takeaways

• Ardeparin sodium was an FDA-approved low-molecular-weight heparin developed as Normiflo by Wyeth-Ayerst.
• The product did not establish a durable U.S. commercial franchise and was later withdrawn.
• Current U.S. revenue, market share, and branded-exclusivity value are effectively absent.
• No material current Orange Book, Paragraph IV, biosimilar, licensing, or settlement activity is associated with ardeparin sodium.
• The patent estate has little current defensive value; manufacturing and regulatory complexity are the main entry barriers.
• Enoxaparin and other established anticoagulants had stronger commercial positioning and limited ardeparin’s differentiation.
• Any re-entry would require a new economic rationale, such as a lower-cost manufacturing platform, differentiated formulation, or narrowly defined clinical use.

FAQs

Is ardeparin sodium still available in the United States?

No. Ardeparin sodium is not a current U.S. marketed anticoagulant. Normiflo was withdrawn after its original FDA approval.

Was ardeparin sodium ever FDA approved?

Yes. The product received FDA approval under NDA 20-946 in the 1990s for postoperative thromboprophylaxis.

Can a company launch a generic version of ardeparin sodium?

A generic launch could be theoretically possible, but regulatory reference-product issues, injectable manufacturing requirements, clinical comparability, and limited market demand create substantial commercial barriers.

Is ardeparin sodium a biosimilar?

No. Ardeparin sodium is not treated as a biosimilar reference product. A potential follow-on product would require evaluation under the applicable drug pathway rather than the standard biosimilar pathway.

Does ardeparin sodium have investment value today?

Its direct commercial value is low. Any residual value would depend on a new development strategy involving manufacturing economics, a differentiated formulation, a geographic market, or a narrowly defined medical use.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Ardeparin sodium injection, NDA 20-946.
2. U.S. Food and Drug Administration. (n.d.). FDA drug approval and withdrawal records for Normiflo (ardeparin sodium).
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.